Danish drug maker Novo Nordisk and e-Therapeutics have signed a collaboration agreement to leverage the latter’s network-driven drug discovery platform (NDD). This will be for the identification of new therapeutic approaches to treat Type 2 diabetes, which accounts...
Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that the...
See the PharmaLetter for a update on the Roche deal with SQZ. Based in Watertown, Massachusetts, SQZ was formed in 2013 and has raised over $100 million. SQZ Biotechnologies is a Massachusetts-based, privately held company developing cellular therapies for multiple...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
